ArticleTissue engineering and regenerative medicine2025
Hyaluronic Acid-Modified N,N,N-trimethyl Chitosan-Poly (β-Aamino Ester) Nanocarriers Loaded with miR210 for Targeted Inhibition of Renal Fibrosis.
Article in Tissue engineering and regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing anti-fibrotic therapy: nanomedicine approaches to overcome current limitations.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe clinical application of miR210, which possesses the capability to effectively alleviate renal interstitial fibrosis (RIF), is greatly constrained by its poor stability and lack of targeting abilities.
methodsA hyaluronic acid-modified N,N,N-trimethyl chitosan-poly (β-amino ester) nanoparticle encapsulating miR210 (HTP@miR210) was constructed. The serum stability, microscopic morphology, particle size, and zeta potential were characterized through gel electrophoresis, transmission electron microscopy, and dynamic light scattering. Subsequently, the cellular uptake capacity and targeting ability of the NPs were evaluated through fluorescence imaging. Furthermore, the biosafety was assessed via CCK-8 experiment, hemolysis test, and comprehensive blood chemistry examinations. Additionally, a TGF-β1-induced RIF cell model was established, and the therapeutic potential of HTP@miR210 against RIF in vitro was evaluated through qRT-PCR, Transwell assays, tube formation experiments, and Western blot (WB). Finally, a unilateral ureteral obstruction (UUO) rat model was constructed, and the therapeutic activity of HTP@miR210 against RIF was further verified using qRT-PCR, H&E staining, Masson's trichrome staining, immunohistochemistry, Flow cytometry (FCM), and WB.
resultsHTP@miR210 exhibited a regular spherical shape. It demonstrated good stability in serum, as well as excellent biocompatibility and hemocompatibility. Additionally, it showed favorable renal targeting and promoted cell proliferation and angiogenesis. In animal experiments, HTP@miR210 effectively improved renal function and alleviated RIF. Specifically, it upregulated the expression of CD31 to promote angiogenesis and effectively inhibited the expression of α-SMA and fn1.
conclusionsThis study underscored the tremendous potential of HTP@miR210 as an effective therapeutic approach for the treatment of RIF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.